Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Grössmann N, Wolf S. Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions Currently, no cost estimates are available for neratinib neither in the US nor in Europe. However, additional costs for possible prospective biomarkers as well as increased costs due to the treatment and monitoring of possible gastrointestinal and cardiac toxicities are likely to incur. Although neratinib offers an improvement in invasive DFS, the gastrointestinal toxicities in combination with possible cardiac toxicities suggest an unfavourable benefit-risk ratio. Further studies are needed to determine the appropriate patient population, to verify the long-term benefit, and to exclude toxic effects of the cardiovascular system. Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Combined Modality Therapy; Humans; Quinolines; Trastuzumab Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32017000166 Date abstract record published 04/04/2017 |